**Table S1**: Missing outcome data on prostate cancer (PCa) risk profiles among Black and non-Hispanic White (NHW) men diagnosed with first primary invasive PCa from 2004 to 2017 in California, using 4 risk categorizations as separate outcomes (prostate specific antigen [PSA], Gleason score [GS], stageand risk\*), by age

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Risk categories and age at diagnosis | |  | NHW men | | | | | |  | | Black men | | | | | | | |  | Black men and NHW men | | | | | | | | | | |
|  | Outcome missing (%) | |  | | Total | |  | | Outcome missing  (%) | | | | | |  | Total | | | |  | Outcome missing (%) | | | | | |  | Total | |
| ***PSA outcome models*** | |  |  |  |  |  | |  | |  | |  |  |  |  |  | | | |  |  | | |  |  |  |  | | | |  |
| Age at diagnosis (y) | |  |  |  |  |  | |  | |  | |  |  |  |  |  | | | |  |  | | |  |  |  |  | | | |  |
| <55 | |  | 7.0 |  |  |  | | 12,555 | |  | | 6.2 |  |  |  | 3,818 | | | |  | 6.8 | | |  |  |  | 16,373 | | | |  |
| 55-64 | |  | 7.5 |  |  |  | | 48,011 | |  | | 6.8 |  |  |  | 9,288 | | | |  | 7.4 | | |  |  |  | 57,299 | | | |  |
| 65-74 | |  | 9.5 |  |  |  | | 57,038 | |  | | 8.3 |  |  |  | 7,681 | | | |  | 9.3 | | |  |  |  | 64,719 | | | |  |
| 75+ | |  | 18.0 |  |  |  | | 29,285 | |  | | 14.9 |  |  |  | 2,768 | | | |  | 17.7 | | |  |  |  | 32,053 | | | |  |
| ***GS outcome models***  Age at diagnosis (y) | |  |  |  |  |  | |  | |  | |  |  |  |  |  | | | |  |  | | |  |  |  |  | | | |  |
| <55 | |  | 4.4 |  |  |  | | 12,555 | |  | | 4.1 |  |  |  | 3,818 | | | |  | 4.3 | | |  |  |  | 16,373 | | | |  |
| 55-64 | |  | 4.3 |  |  |  | | 48,011 | |  | | 4.8 |  |  |  | 9,288 | | | |  | 4.4 | | |  |  |  | 57,299 | | | |  |
| 65-74 | |  | 5.1 |  |  |  | | 57,038 | |  | | 5.1 |  |  |  | 7,681 | | | |  | 5.1 | | |  |  |  | 64,719 | | | |  |
| 75+ | |  | 10.2 |  |  |  | | 29,285 | |  | | 10.8 |  |  |  | 2,768 | | | |  | 10.2 | | |  |  |  | 32,053 | | | |  |
| ***Stage outcome models***  Age at diagnosis (y) | |  |  |  |  |  | |  | |  | |  |  |  |  |  | | | |  |  | | |  |  |  |  | | | |  |
| <55 | |  | 1.6 |  |  |  | | 12,555 | |  | | 1.3 |  |  |  | 3,818 | | | |  | 1.5 | | |  |  |  | 16,373 | | | |  |
| 55-64 | |  | 1.9 |  |  |  | | 48,011 | |  | | 2.4 |  |  |  | 9,288 | | | |  | 2.0 | | |  |  |  | 57,299 | | | |  |
| 65-74 | |  | 2.7 |  |  |  | | 57,038 | |  | | 3.1 |  |  |  | 7,681 | | | |  | 2.7 | | |  |  |  | 64,719 | | | |  |
| 75+ | |  | 6.0 |  |  |  | | 29,285 | |  | | 6.8 |  |  |  | 2,768 | | | |  | 6.1 | | |  |  |  | 32,053 | | | |  |
| ***Risk outcome models***  Age at diagnosis (y) | |  |  |  |  |  | |  | |  | |  |  |  |  |  | | | |  |  | | |  |  |  |  | | | |  |
| <55 | |  | 7.7 |  |  |  | | 12,555 | |  | | 6.9 |  |  |  | 3,818 | | | |  | 7.5 | | |  |  |  | 16,373 | | | |  |
| 55-64 | |  | 8.0 |  |  |  | | 48,011 | |  | | 7.0 |  |  |  | 9,288 | | | |  | 7.9 | | |  |  |  | 57,299 | | | |  |
| 65-74 | |  | 9.7 |  |  |  | | 57,038 | |  | | 8.3 |  |  |  | 7,681 | | | |  | 9.5 | | |  |  |  | 64,719 | | | |  |
| 75+ | |  | 15.3 |  |  |  | | 29,285 | |  | | 12.6 |  |  |  | 2,768 | | | |  | 15.0 | | |  |  |  | 32,053 | | | |  |
| \* PCa risk stratification criteria based on the NCCN classification using TNM stage, GS and PSA level. | | | | | | | | | | | | | | | | | | | | | | | | | | |
|  | | | | | | | | | | | | | | | | | | | | | | | | | | |